Reported Patient Death in an Innovative CRISPR Trial – Client Update – January 2026
Dear Clients,
Recent public reporting on a patient death in an innovative CRISPR trial and subsequent FDA clinical hold activity highlights how quickly a single safety event can evolve into a multitrack company issue.
Our client update sets out practical takeaways for Israeli sponsors on governance, vendor coordination, documentation discipline, and consistent communications across stakeholders.
We remain at your disposal to provide legal counsel on any matters arising from the developments and to assist as needed.
Agmon With Tulchinsky
More Relevant Media
15.01.2026
Reported Merck Interest in Revolution Medicines – Market Signals for 2026 Biotech M&A Deal Structures and Negotiation Strategy
Client updates
29.12.2025
EU Commission’s Medical Devices Regulation Simplification Proposal and EUDAMED Mandatory Modules Timeline
Client updates
21.07.2025
Amendment to the Medical Information Portability Law, 5784-2024 – Client Update – July 2025
Client updates
09.01.2025
FDA Guidance – Clinical Trial Diversity Action Plans – Client Update – January 2025
Client updates